Italy Launches National Screening Program to Detect Type 1 Diabetes Early in Children

Type 1 diabetes doesn't appear overnight. For months or years before symptoms show up, the immune system quietly attacks the cells in the pancreas that make insulin. Scientists have learned to detect these early immune attacks by testing for specific antibodies in the blood.

Italy is now implementing a national screening program based on this science. Starting with children ages 5-6, the program will test for pancreatic autoantibodies using small blood samples. The goal is to identify children during this presymptomatic stage—before they become seriously ill—so doctors can monitor them closely and families can prepare.

The program was established under Italian Law 130/2023 and became active in late 2025. It represents one of the most comprehensive population-based screening efforts for Type 1 diabetes in Europe.

The program uses a streamlined two-level approach. Regional laboratories across Italy perform the initial screening on capillary blood samples—small amounts taken from a finger prick—using standardized, high-throughput antibody tests. This allows the program to screen large numbers of children efficiently.

If the regional lab finds autoantibodies, the sample goes to a national reference laboratory for confirmation. These reference labs use different, more specific testing methods to verify the result and reduce false positives. This confirmation step is crucial for ensuring that families receive accurate information.

Children whose results are confirmed positive are then referred to pediatric diabetes centers. There, doctors perform additional metabolic testing to understand how far the autoimmune process has progressed and establish a plan for ongoing monitoring.

One of the most serious complications of undiagnosed Type 1 diabetes is diabetic ketoacidosis (DKA), a condition where the body's chemistry becomes dangerously imbalanced. DKA can develop rapidly and requires emergency care. Early screening aims to prevent children from reaching this point.

Beyond preventing emergencies, early identification allows families and doctors to monitor at-risk children over time. Some children with autoantibodies may not develop clinical diabetes for years, while others progress more quickly. Understanding this timeline helps families prepare and ensures children receive timely care if their condition advances.

One challenge in population screening is ensuring that results are consistent and reliable across different laboratories and regions. The Italian program addresses this by combining decentralized screening—performed locally for convenience—with centralized confirmation and standardized procedures.

The program establishes clear protocols for how samples are collected, tested, and interpreted. It also creates pathways for sharing information between regional and national reference centers. This coordination helps ensure that every child gets the same high standard of care, regardless of where they live in Italy.

If your child is in the screening age group in Italy, you may be invited to participate. A positive screening result does not mean your child has Type 1 diabetes. It means your child has autoantibodies associated with increased risk. Many children with these antibodies will not develop diabetes for years, if at all.

A confirmed positive result leads to referral to a diabetes center for monitoring and metabolic assessment. This allows your child's medical team to track changes over time and help your family prepare, should diabetes develop. The goal is early knowledge and coordinated care—not premature treatment.

Source: Clinical chemistry and laboratory medicine. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.